Bivalent Respiratory Syncytial Virus prefusion F vaccine(Pfizer)

呼吸道合胞病毒疫苗（辉瑞）

Report date: 2026/05/11 20:01:57

Base Information

Drug NameBivalent Respiratory Syncytial Virus prefusion F vaccine(Pfizer)
Drug Alias NameRespiratory syncytial virus (RSV) prefusion F subunit vaccine(Pfizer)Respiratory syncytial virus vaccine(Pfizer)RSV Vaccine(Pfizer)RSVpreF (Pfizer)ABRYSVO +[7] 
ClassificationVaccines > Application > Prophylactic vaccineVaccines > Development/production technology > Genetically engineered subunit vaccineVaccines > Biological material > Viral vaccine +[4] 
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsRespiratory Tract DiseasesRespiratory Syncytial Virus InfectionsRespiratory Tract Infections
Global Approved IndicationsRespiratory Syncytial Virus Infections
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2023/05/31
Country/TerritoryCanadaUnited StatesTaiwan +[21] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaDiscontinued
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesPfizer IncPfizer Japan IncPfizer Europe Ma Eeig
Inactive CompaniesPfizer Manufacturing Belgium NvPfizer Investment Co Ltd
Active IndicationsRespiratory Syncytial Virus InfectionsRespiratory Tract Infections
Inactive IndicationsRespiratory Tract Diseases

Other Information

ATC CodeN/A
Related LinksN/A